Literature DB >> 20358436

Sample size calculation for thorough QT/QTc study considering various factors related to multiple time points.

Zhaoling Meng1, Robert Kringle, Xun Chen, Peng-Liang Zhao.   

Abstract

The sample size requirement in a thorough QT/QTc study is discussed under a balanced parallel or crossover study design. First, we explore the impacts of various factors on the study power, including the mean effect profile across time and correlation among time points. Then we estimate the variability parameters needed based on multiple historical studies. Different baseline usage is illustrated to have a significant impact on the analysis variability in the parallel studies. Finally, the sample size calculations and recommendations are given for demonstrating a "negative" drug effect and the study assay sensitivity, respectively.

Mesh:

Year:  2010        PMID: 20358436     DOI: 10.1080/10543400903582000

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  4 in total

1.  Dabigatran does not prolong the QT interval with supratherapeutic exposure: a thorough QT study in healthy subjects.

Authors:  Arne Ring; Karin Rathgen; Joachim Stangier; Paul Reilly; Andreas Clemens; Jeffrey Friedman
Journal:  Clin Drug Investig       Date:  2013-05       Impact factor: 2.859

2.  Concentration-QTc analysis with two or more correlated baselines.

Authors:  Yasushi Orihashi; Yuji Kumagai
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-05-12       Impact factor: 2.745

3.  Concentration-QTc analysis for single arm studies.

Authors:  Yasushi Orihashi; Shoichi Ohwada; Yuji Kumagai
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-01-29       Impact factor: 2.745

4.  The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study.

Authors:  Arne Ring; Tobias Brand; Sreeraj Macha; Kerstin Breithaupt-Groegler; Gudrun Simons; Beate Walter; Hans J Woerle; Uli C Broedl
Journal:  Cardiovasc Diabetol       Date:  2013-04-24       Impact factor: 9.951

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.